Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $9.50 Consensus PT from Analysts

Posted by on Sep 2nd, 2026

Cardiol Therapeutics Inc. (NASDAQ:CRDL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the four research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $10.00.

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group increased their target price on shares of Cardiol Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. HC Wainwright restated a “buy” rating on shares of Cardiol Therapeutics in a research report on Tuesday, July 14th. B. Riley Financial started coverage on Cardiol Therapeutics in a research note on Wednesday, August 26th. They set a “buy” rating and a $11.00 price objective for the company. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Wednesday, June 24th.

Get Our Latest Stock Report on CRDL

Institutional Investors Weigh In On Cardiol Therapeutics

Several hedge funds have recently modified their holdings of the stock. Royal Bank of Canada grew its position in Cardiol Therapeutics by 62.3% in the 1st quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock valued at $29,000 after buying an additional 8,306 shares during the last quarter. PVG Asset Management Corp raised its position in Cardiol Therapeutics by 10.3% during the 1st quarter. PVG Asset Management Corp now owns 107,165 shares of the company’s stock worth $145,000 after buying an additional 10,000 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after acquiring an additional 15,255 shares during the period. Simplex Trading LLC lifted its stake in shares of Cardiol Therapeutics by 96.9% in the 4th quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock worth $31,000 after acquiring an additional 15,842 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new stake in shares of Cardiol Therapeutics in the second quarter valued at about $27,000. 12.49% of the stock is owned by institutional investors and hedge funds.

Cardiol Therapeutics Trading Up 8.9%

Shares of NASDAQ CRDL opened at $2.15 on Wednesday. The stock has a market cap of $249.16 million, a P/E ratio of -8.60 and a beta of 0.79. Cardiol Therapeutics has a twelve month low of $0.88 and a twelve month high of $2.27. The stock has a 50 day moving average of $1.39 and a two-hundred day moving average of $1.26.

Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. As a group, research analysts predict that Cardiol Therapeutics will post -0.23 earnings per share for the current year.

Cardiol Therapeutics Company Profile

(Get Free Report)

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

Further Reading

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.